Drug Trial Radar · NCT04035005
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,013
Actual
Start
Aug 12, 2019
Primary completion
Jan 15, 2025
Study completion Apr 15, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study will consist of the following phases: screening, double-blind treatment, an optional post-double-progression ocrelizumab (PDP OCR) treatment, follow-up 1 (FU1), an optional open-label extension (OLE), and follow-up 2 (FU2).
Conditions
- Multiple Sclerosis, Primary Progressive
Interventions
OcrelizumabDrug
The first dose of ocrelizumab will be administered as two 300 milligrams (mg), IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusion, should be maintained between each infusion.
PlaceboDrug
The first dose of placebo will be administered as two IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusions, maintained between each infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FASTime frame: Up to approximately 243 weeks
- Time to Onset of cCDP12 in Magnetic Resonance Imaging (MRI) Activity Analysis SetTime frame: Up to approximately 243 weeks
Locations
153 sites in 23 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia
MS and Neuromuscular Center of Excellence
Clearwater, Florida
Neurological Services of Orlando
Orlando, Florida
Vero Radiology Associates
Vero Beach, Florida
University of Kansas Medical Center
Kansas City, Kansas
The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
Columbus, Ohio
Columbus Neuroscience
Westerville, Ohio
Albert Einstein Medical Center
Philadelphia, Pennsylvania
Brain and Mind Research Institute
Camperdown, New South Wales, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Cliniques Universitaires St-Luc
Brussels, Belgium
MS & Neurologisch Revalidatie Centrum
Overpelt, Belgium
UZ Antwerpen
Edegem, Antwerpen, Belgium
Military Medical Academy HBAT
Pleven, Bulgaria
Multiprofile Hospital For Active Treatment Avis Medica
Pleven, Bulgaria
Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD
Sofia, Bulgaria
University of Alberta
Edmonton, Alberta, Canada
Dalhousie Multiple Sclerosis Research Unit
Halifax, Nova Scotia, Canada
BARLO MS Centre at St. Michael?s Hospital
Toronto, Ontario, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia
Bogotá, Colombia
?Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico?
Medellín, Antioquia, Colombia
General Hospital Varazdin
Varaždin, Croatia
Clinical Hospital Sestre Milosrdnice
Zagreb, Croatia
University Hospital Center Zagreb
Zagreb, Croatia
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France
Centre Hospitalier Universitaire de Clermont Ferrand
Clermont-Ferrand, France
CHRU Nancy
Nancy, France
Hopital Guillaume Et Rene Laennec
Nantes, France
CHU de Nimes - Hopital Universitaire Caremeau
Nîmes, France
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, Alsace, France
Pineo Medical Ecosystem LTD
Tbilisi, Georgia
The First University Clinic of Tbilisi State Medical University
Tbilisi, Georgia
Khechinashvili University Hospital
Tbilisi, Georgia
AOU dell Universita degli Studi della Campania Luigi Vanvitelli Piazza Luigi Miraglia 2
Naples, Campania, Italy
Azienda Ospedaliera Sant'andrea
Rome, Lazio, Italy
IRCCS AOM Azienda Ospedaliera Metropolitana
Genoa, Liguria, Italy
Ospedale San Raffaele S.r.l. - PPDS
Milan, Lombardy, Italy
Fondazione Istituto Neurologico Mondino IRCCS
Pavia, Lombardy, Italy
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.